Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

55.6%

5 terminated/withdrawn out of 9 trials

Success Rate

28.6%

-57.9% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

150%

3 of 2 completed trials have results

Key Signals

2 recruiting3 with results

Enrollment Performance

Analytics

Phase 1

7(77.8%)

Phase 2

2(22.2%)

9Total

Phase 1(7)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06265688Phase 1Recruiting

First In Human Study of CX-2051 in Advanced Solid Tumors

Role: lead

NCT06462794Phase 1Recruiting

First In Human Study of CX-801 in Advanced Solid Tumors

Role: lead

NCT03993379Phase 2Terminated

PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors

Role: lead

NCT05387265Phase 1Terminated

A Trial to Find Safe and Active Doses for an Investigational Drug, CX-904, for Patients With Advanced Solid Tumors

Role: lead

NCT03013491Phase 1Terminated

PROCLAIM-CX-072: A Trial to Find Safe and Active Doses of an Investigational Drug CX-072 for Patients With Solid Tumors or Lymphomas

Role: lead

NCT04596150Phase 2Completed

Study to Evaluate the Safety and Antitumor Activity of CX-2009 Monotherapy and in Combination With CX-072 in Advanced Breast Cancer

Role: lead

NCT03543813Phase 1Completed

PROCLAIM-CX-2029: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2029 for Patients With Solid Tumors or DLBCL

Role: lead

NCT03149549Phase 1Terminated

PROCLAIM-CX-2009: A Trial to Find Safe and Active Doses of an Investigational Drug CX-2009 for Patients With Selected Solid Tumors

Role: lead

NCT03706274Phase 1Withdrawn

PROCLAIM-CX-188: A Trial to Find Safe and Active Doses of an Investigational Drug CX-188 for Patients With Solid Tumors

Role: lead

All 9 trials loaded